1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Bactiguard Holding AB

Bactiguard Holding AB

15.80
SEK
+1.40
(+9.72%)
-0.27EPS
553.69MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12,673.3
3.74
3.95
3.57
4.43
4.51
5.55
5.14
4.84
6.47
5.82
6.9
6.16
5.93
Basic EPS, GAAP
-340.7
-4.43
-0.8
-0.81
-0.1
-0.45
0.49
-1.14
-1.68
-1.51
-3.95
-0.85
-0.22
-0.27
Free Cash Flow per Basic Share
-5,415.1
-2.15
-0.97
-0.6
-0.86
-0.15
1.49
-0.44
- -
-0.22
-1.74
0.29
-0.21
0.39
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8,073.6
13.3
12.53
11.72
11.62
11.14
11.61
11.13
15.45
14.15
10.08
9.37
8.99
8.69
Tangible Book Value per Share
-50,242.9
-3.5
-3.64
-3.83
-3.22
-3.04
-1.82
-2.4
3.28
2.83
-0.1
-0.11
0.4
0.44
Basic Weighted Avg Shares
- -
25
33
33
33
33
33
34
35
35
35
35
35
35
Sales/Revenue/Turnover
127
94
131
119
147
150
185
172
169
227
204
242
216
208
Operating Margin (%)
7.22
-41.22
-12.41
-18.86
-0.4
-11.81
9.61
-11.28
-32.05
-23.92
-67.26
-15.81
-3.49
-4.66
Depreciation Expense
29
30
33
33
35
34
42
44
47
49
40
47
47
27
Net Income, GAAP
-3
-111
-27
-27
-3
-15
16
-38
-59
-53
-138
-30
-8
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2.69
-118.4
-20.17
-22.61
-2.2
-9.95
8.79
-22.28
-34.68
-23.32
-67.84
-12.34
-3.63
-4.5
Working Capital
-51
76
-124
-72
37
30
-72
76
258
224
-63
-87
50
46
LT Debt
428
196
- -
50
155
142
72
254
238
228
42
41
149
143
Total Equity
81
443
417
390
387
371
387
373
541
496
353
328
315
304
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-3.02
-42.3
-6.16
-6.65
-0.84
-3.94
4.29
-10.1
-12.85
-10.2
-32.6
-8.75
-2.44
-3.01

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
14
14
LT Borrowings
119
121
119
LT Finance Leases
29
26
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
697
573
554

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
124
122
116
Cash, Cash Equivalents & STI
44
35
44
Accounts Receivable, Net
36
36
25
Inventories
22
26
27
Total Current Liabilities
74
73
70
Payables & Accruals
- -
- -
- -
ST Debt
14
14
14
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.4%
-0.66%
-4.08%
Free Cash Flow
1,901%
4,066.45%
-170.58%
Net Income, GAAP
-21.97%
10.53%
-73.69%
Sales/Revenue/Turnover
6.26%
5.98%
-10.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
54
57
67
63
242
2025
59
48
- -
63
216
2026
42
54
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.28
-0.41
-0.13
-0.03
-0.85
2025
-0.13
-0.23
- -
0.36
-0.22
2026
-0.16
-0.23
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Christine Lind
Full Time Employees
159
Sector
Health technology
Industry
Medical specialties
Address
Vasagatan 11 Tullinge SD Sweden 111 20
IPO Date
Jun 19, 2014
Website
bactiguard.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bactiguard Holding AB (publ) is a Sweden-based MedTech company that develops and licenses infection prevention technology for medical devices; its core offering is the patented Bactiguard Infection Protection (BIP) coating, an ultra-thin noble metal alloy of gold, palladium and silver that prevents bacterial adhesion and biofilm formation. The company provides this technology across urology, orthopedics, cardiology, neurology and other segments through licensing partnerships with leading MedTech firms including Becton Dickinson for urinary catheters such as Bardex IC and Lubrisil IC, Well Lead Medical for catheters and tubes, and Zimmer Biomet for orthopedic trauma implants; it also markets a wound management portfolio featuring Hydrocyn aqua antimicrobial solutions and gels for wound healing and disinfection, alongside sutures including non-absorbable, natural absorbable, synthetic absorbable and specialty types, as well as other wound care products distributed locally. Founded in 2005 and headquartered in Stockholm, Sweden, Bactiguard operates globally with products and licensed solutions available in multiple countries through its partners and distributors. In recent developments, the company reported continued EBITDA profitability in its third quarter 2025 interim results with SEK 5.3 million, despite a 34.5% revenue decline to SEK 48.4 million due to currency effects and prior-year highs, alongside growth in Hydrocyn aqua offsetting suture declines; it completed a strategic transformation in 2024 with updated financial targets emphasizing license business growth and profitability, new leadership under CEO Christine Lind, and strengthened clinical evidence for future expansion.